^IXIC
EQS Group
Polyphor receives approval to start first-in-human clinical trial of inhaled antibiotic murepavadin
Polyphor AG / Key word(s): Study
22-Dec-2020 / 07:30 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
Allschwil, Switzerland, December 22, 2020
- Phase I safety, tolerability, and pharmacokinetic study in healthy volunteers expected to start in coming weeks following acceptance of a request for a Clinical Trial Authorization (CTA) granted by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
- Polyphor's inhaled murepavadin is a novel class antibiotic that specifically targets Pseudomonas aeruginosa lung infections in people with cystic fibrosis (CF).
- Phase I development in healthy volunteers is jointly funded by Polyphor and the European Innovative Medicines Initiative (IMI).
Polyphor AG (SIX: POLN) today announced that the UK Medicines and Healthcare products regulatory agency (MHRA) has granted a CTA (Clinical Trial Authorization) to start the first-in-human Phase I study of its novel class antibiotic murepavadin, delivered via the oral inhalation route.
The Phase I study is part of the clinical development plan exploring the inhaled formulation of murepavadin to treat Pseudomonas aeruginosa infections in people with cystic fibrosis, including resistant bacterial strains. The study is expected to enroll the first patient in the coming weeks. The safety, tolerability, and pharmacokinetic study is using eFlow(R) Technology nebulizer (PARI Pharma GmbH) to administer murepavadin Inhalation Solution (MIS) in healthy volunteers.
"We are very excited to further expand Polyphor's clinical pipeline with the initiation of this study in a rare disease indication beyond our Phase III immuno-oncology program with balixafortide in advanced metastatic breast cancer. Patients with CF urgently need new antibiotic options against Pseudomonas aeruginosa infection which is the most important pathogen in progressive and severe CF lung disease", said Dr. Frank Weber, Chief Medical and Development Officer at Polyphor. "Inhaled murepavadin has the potential to address this need and we would like to thank the European Innovative Medicines Initiative and the CF Foundation for their tremendous support and guidance in the development of this innovative program."
Polyphor's inhaled murepavadin is currently being developed as a precision antibiotic specifically for the treatment of chronic Pseudomonas aeruginosa infections in people with CF. It is the first member of the Outer Membrane Protein Targeting Antibiotics (OMPTA), a novel class of antibiotics which was discovered by Polyphor and the University of Zurich and displays a unique mode of action. Based on the data of the inhaled murepavadin preclinical program suggesting significantly higher safety margins (at least 5-10 times) versus the intravenous formulation, Polyphor is initiating a clinical development program in CF. The Phase I study, evaluating safety and tolerability (both overall and local) of single and multiple ascending doses of inhaled murepavadin in healthy volunteers, is jointly funded by Polyphor and the European Innovative Medicines Initiative (IMI). A Phase Ib/IIa trial in adults with CF, assessing safety and tolerability of ascending doses of inhaled murepavadin, is planned to be initiated following completion of the Phase I study in 2021. A recently granted award from the Cystic Fibrosis Foundation will allow further development until the end of the Phase Ib/IIa study. Inhaled murepavadin is also part of the iABC project, a Europe-wide program dedicated to the development of inhaled antibiotics run by a consortium of leading lung specialists and research institutions in various European countries.
Infections remain a significant problem for people with CF who require novel treatment options, despite the availability of CFTR modulators. If approved for commercial use, inhaled murepavadin would be the first new class of antibiotics for Gram-negative pathogens in the last 50 years. It would also be potentially the first agent to target specifically Pseudomonas aeruginosa bacteria versus the current standard of care, broad spectrum inhaled antibiotics.
For Media:
LifeSci Advisors
bschmid@lifesciadvisors.com
About Polyphor
Polyphor is a research-driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance leveraging the company's leading macrocyclic peptide technology platform. Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company's lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit www.polyphor.com.
This press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor's results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.
End of ad hoc announcement
Hernan Levett
Polyphor Ltd.
IR@polyphor.com
Mary-Ann Chang
mchang@lifesciadvisors.com
Polyphor AG
Hegenheimermattweg 125
4123 Allschwil
info@polyphor.com
www.polyphor.com
POLN
EQS Group News Service
show this
Fox News' Chris Wallace Says Biden's Was The 'Best Inaugural Address I Ever Heard'
American Tower Corporation Announces Tax Reporting Information for 2020 Distributions
Charges against anti-government extremists and pro-Trump gang members show a coordinated attack on the democratic process.
The anchor also made a pointed comment about the president's words on "lies that are told for power and ... for profit."
American Tower Corporation (NYSE: AMT) today announced year-end tax reporting information for its 2020 distributions. Stockholders are urged to consult with their personal tax advisors as to their specific tax treatment.
ECB to chart steady course even as the outlook dulls
The European Central Bank will keep its easy money policy unchanged on Thursday but hold the door wide open to further stimulus as the spreading second wave of COVID-19 dims an already weak outlook. Having extended stimulus well into next year with a massive support package in December, ECB policymakers are keen to pass the baton to governments and fiscal policy to keep the euro zone economy afloat until normal business activity can resume. But fresh lockdowns, a slow start to vaccinations across the 19 countries that use the euro, and the currency's strength will increase headwinds for exporters, challenging the ECB's forecasts of a robust recovery starting in the second quarter.
Should You Keep Your Amex Platinum Card if You Don't Plan to Travel This Year?
The past year has been a rough one for frequent travelers, and credit card lovers have seen their beloved travel credit cards lose a lot of value while they're stuck at home. Due to its steep annual fee, it's one of the harder cards to justify keeping open if you aren't traveling. Chase has made plenty of changes to its premium travel credit cards over the past year to make sure cardholders are still getting enough value without traveling.
Income-seeking investors looking ahead to a post-COVID-19 world may find potential in safe bank stocks that struggled during 2020 at the height of the pandemic. As global vaccinations slowly roll out, still-depressed bank stocks offer attractive yields with the bonus of eventual share price growth. Operating in 11 western states, Zions Bancorporation (NASDAQ: ZION) provides a nice example of this potential.
Gregor Townsend delight after Cameron Redpath declares for Scotland
AM Best Comments on Credit Ratings of Talcott Resolution Life, Inc. and Its Subsidiaries Following Acquisition Announcement
AM Best has commented that the Credit Ratings (ratings) of Talcott Resolution Life, Inc. (Delaware) and its insurance subsidiaries, Talcott Resolution Life Insurance Company (Windsor, CT) and Talcott Resolution Life and Annuity Insurance Company (Windsor, CT) (collectively known as Talcott Resolution), remain unchanged following the announcement that Sixth Street, a leading global investment firm with over $50 billion in assets under management and committed capital, has entered into a definitive agreement to acquire Talcott Resolution from a consortium of investors led by Cornell Capital LLC, Atlas Merchant Capital LLC, TRB Advisors LP, Global Atlantic Financial Group Limited, Pine Brook, J. Safra Group and The Hartford Financial Services Group. The Long-Term Issue Credit Ratings of Talcott Resolution Life, Inc. also remain unchanged. The outlook of these ratings remains stable.
India's IndiGo has emerged as one of the world's biggest airlines by capacity, aided by a swift recovery in the domestic aviation market to nearly 80% of pre-pandemic levels and the financial strength to boost market share as rivals struggle. IndiGo took 44 planes from Airbus SE last year - the most of any customer and topping Delta Air Lines Inc and China Southern Airlines Co Ltd - as it replaced older planes with more fuel-efficient newer models. With a 52% domestic market share in 2020 versus 47% in 2019, and profitability in sight after a loss last fiscal year, IndiGo is expanding its reach to smaller Indian cities such as Ranchi, Patna and Gorakhpur to replace a fall in business travel on larger routes like New Delhi-Mumbai, CEO Ronojoy Dutta told Reuters.
Gold and Copper Climb as Dollar Weakens With Eyes on Inflation
(Bloomberg) -- Gold and copper surged as the dollar weakened amid signs that interests rates may remain low, boosting inflation expectations as Joe Biden begins his first day as U.S. president.The Bloomberg Dollar Spot index extended declines for a third straight day on Wednesday, supporting prices of commodities priced in the greenback. Stocks rose and bond yields tied to inflation expectations held gains from Tuesday, when Biden's Treasury Secretary nominee Janet Yellen said that a slew of state spending was needed to fight the Covid-19 pandemic, while playing down concerns about the debt it creates."Precious metals were supported above all by a weaker U.S. dollar, which fell further on the back of renewed strength for stock markets," Fawad Razaqzada, a market analyst at ThinkMarkets, said in a note. "The path of least resistance is now to the upside again," with gold trading above last week's high and finding support above its 200-day moving average, he said.Yellen's Tuesday testimony was key in weakening the dollar while lifting gold and base metal prices, according to Commerzbank analysts Carsten Fritsch and Daniel Briesemann. Copper had additional support on signs of greater risk appetite, the bank said. Industrial metals have been helped by expectations of increased Chinese and U.S. demand as Covid-19 vaccines continue to be be distributed and economies recover, ramping up spending on raw goods."The metals prices are supported by the further rising stock markets, which express the high risk appetite of market participants," Briesemann said. "This is fed by hopes that economic life will return to normal with the vaccinations that have now begun."Biden became the 46th U.S. president in Wednesday's inaugural ceremony that unfolded under heavy security after weeks of tumult and unrest stoked by Donald Trump. Next, traders will be looking toward the president's ability to pass his economic stimulus plans through Congress, which would fuel another surge in metals demand in the U.S., the second-largest metals consumer after China."All else being equal, a Biden presidency supported by control of the House and Senate, ought to be very favorable for gold," Bryan Slusarchuk, chief executive officer of Fosterville South Exploration Ltd., said in an email.With Democratic leaders pushing for nearly $2 trillion in stimulus, there are "very big signals that the proverbial kitchen sink is about to be thrown at an effort to prop up a fragile economy, an effort that may have short-term impact but in the long term will cause further pain and ultimately will be negative for the U.S. dollar and positive for gold," Slusarchuk said.Spot gold rose 1.7% to $1,871.84 an ounce by 5 p.m. in New York. Silver, platinum and palladium also pushed higher. Copper prices closed 1.1% higher at $8,044.50 a metric ton on the London Metal Exchange, with all major base metals rising. The Bloomberg Dollar Spot Index dropped 0.2%.(An earlier version of this story corrected location of timestamp)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
PNFP earnings call for the period ending December 31, 2020.